EGFR Exon 20-Positive NSCLC Prognosis and Challenges
Alexander Spira, MD, PhD, FACP, discusses the prognosis of patients with EGFR- exon 20 mutated non-small cell lung cancer.
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists, discusses the prognosis of patients with EGFR- exon 20 mutated non-small cell lung cancer (NSCLC).
According to Spira, the prognosis is not as good as other EGFR mutations as there are no targeted therapies. The prognosis of this patient population is similar to that with EGFR wild type.
EGFR-exon 20 mutated NSCLC is treated just like any other lung cancer currently. It is an actionable mutation, and more therapies are needed in order to target it.
0:08 | The prognosis is clearly not as good as other EGFR mutations because there are no targeted therapies. So, it's clearly worse prognosis with an average length of diagnosis, probably similar to wild type patients without the new treatments that are coming.
0:25 | The challenge is before we get some drugs that we are hopefully going to have approved soon, is that it is just treated like other lung cancers. So, we know there's a targeted mutation. And it's been very frustrating because you have a targeted mutation, but you couldn't act on it. So, the hope is that, obviously with some new treatments, we'll be able to change that significantly because were being teased for our patients that we know there's something there, but you can't do
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
March 26th 2024According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Read More
Osimertinib Enhances Progression-Free Survival in Stage III NSCLC
February 19th 2024Osimertinib shows significant progression-free survival improvement in stage III EGFR-mutated non-small cell lung cancer post-chemoradiotherapy, marking a major advance in treatment options for this patient population.
Read More
